| P2860 | cites work | Association of trypanolytic ApoL1 variants with kidney disease in African Americans | Q24606581 |
| | Supramaximal dose of candesartan in proteinuric renal disease | Q24649685 |
| | The role of diastolic blood pressure when treating isolated systolic hypertension | Q28145536 |
| | The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 |
| | Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q28303699 |
| | Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease | Q32066990 |
| | Morbidity and Mortality of Orthostatic Hypotension: Implications for Management of Cardiovascular Disease | Q33159154 |
| | Blood pressure and survival in the oldest old. | Q33277116 |
| | United States Renal Data System 2008 Annual Data Report | Q33396108 |
| | Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. | Q33414957 |
| | Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial | Q33437564 |
| | Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society | Q33816876 |
| | Efficacy and safety of benazepril for advanced chronic renal insufficiency | Q33992851 |
| | Effects of intensive blood-pressure control in type 2 diabetes mellitus | Q34008161 |
| | Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy | Q34396234 |
| | Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy | Q34432806 |
| | Population-based study on the prevalence and correlates of orthostatic hypotension/hypertension and orthostatic dizziness | Q34810442 |
| | initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial | Q35179914 |
| | Arterial stiffness in renal patients: an update | Q36163632 |
| | Ambulatory blood-pressure monitoring | Q36493993 |
| | Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan | Q36662162 |
| | The incidence and implications of aldosterone breakthrough | Q36918649 |
| | Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors | Q37057985 |
| | Hypertension-associated kidney disease: perhaps no more | Q37299028 |
| | Susceptibility genes in common complex kidney disease | Q37616991 |
| | The angiotensin II type 2 receptor in cardiovascular disease | Q37622575 |
| | Home sphygmomanometers: what should a nephrologist know? | Q37741119 |
| | European Society of Hypertension practice guidelines for home blood pressure monitoring. | Q37762443 |
| | Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement | Q37797817 |
| | The conundrum of increased burden of end-stage renal disease in Asians | Q38411892 |
| | Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success? | Q39728537 |
| | Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study | Q39972761 |
| | Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort | Q40331970 |
| | Strict blood-pressure control and progression of renal failure in children | Q43257210 |
| | Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension | Q43586133 |
| | Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk | Q43759322 |
| | Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period | Q43913695 |
| | A low-sodium diet potentiates the effects of losartan in type 2 diabetes | Q43937012 |
| | Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). | Q44192009 |
| | Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study | Q44511770 |
| | Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results | Q45173409 |
| | Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents | Q45198988 |
| | Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study | Q45204771 |
| | Blood pressure control in chronic kidney disease: is less really more? | Q45432316 |
| | Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design | Q46162422 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial | Q46522431 |
| | Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 |
| | Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease | Q46900011 |
| | Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension | Q48267169 |
| | Arterial structure and function in end-stage renal disease | Q48713931 |
| | Adherence to antihypertensive agents and blood pressure control in chronic kidney disease | Q48971003 |
| | Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease | Q50176457 |
| | Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Associati | Q51542873 |
| | Jananese Society of Hypertension (JSH) Guidelines for Self-Monitoring of Blood Pressure at Home | Q51797042 |
| | Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. | Q51943135 |
| | The enigma of hypertensive ESRD: observations on incidence and trends in 18 European, Canadian, and Asian-Pacific populations, 1998 to 2002 | Q53007477 |
| | Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? | Q53253898 |
| | Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. | Q54348402 |
| | Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement | Q57085541 |
| | Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) | Q57396207 |
| | ACE-inhibitor use and the long-term risk of renal failure in diabetes | Q57446641 |
| | Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial | Q57702534 |
| | Diastolic Blood Pressure and Mortality in the Elderly With Cardiovascular Disease | Q60594035 |
| | Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials | Q61873319 |
| | The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide | Q74816907 |
| | Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease | Q79379738 |
| | Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency | Q80313261 |
| | Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients | Q81489212 |
| | Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease | Q81555894 |
| | Home blood pressure monitoring in CKD | Q81853685 |
| | Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease | Q82242344 |
| | Blood pressure control in CKD patients: why do we fail to implement the guidelines? | Q83062895 |
| | Geographic, ethnic, age-related and temporal variation in the incidence of end-stage renal disease in Europe, Canada and the Asia-Pacific region, 1998-2002 | Q83089797 |
| | ONTARGET still OFF-TARGET? | Q83491265 |
| | An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function | Q83751680 |
| | Renal Association Clinical Practice Guideline on detection, monitoring and management of patients with CKD | Q84069692 |
| | Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease | Q84456381 |
| | The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease | Q84699464 |
| | Ambulatory blood pressure monitoring | Q94210258 |
| P433 | issue | 5 | |
| P304 | page(s) | 382-387 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Kidney International Supplements | Q26842881 |
| P1476 | title | Chapter 8: Future directions and controversies | |
| P478 | volume | 2 | |